Over 1,000 Chemotherapy Protocols And Counting

Open-label, multicenter, phase 2 study Unresectable or metasatic ASPS Atezolizumab 1200 mg in adults (n=49) or 15 mg/kg (1200 mg max) in pediatric pts (n=3) once q21 days

20 Nov

GastroEsophageal Cancer

New Reference: Pembrolizumab with Chemotherapy in Advanced Gastric Cancer

Double-blind, multicenter, randomised, phase 3 study (Keynote 859) Previously untreated locally advanced/metastatic HER2 negative GEJ and gastric adenocancer Pembrolizumab + Cht (n

23 Sep

Colorectal Cancer

New Protocol: Trifluridine-Tipiracil and Panitumumab for Refractory RAS WT Colorectal Cancer

Phase II, multicenter (VELO) Patients with refractory RAS WT mCRC Trifluridine-tipiracil +Panitimumab (n=31) vs. Trifluridine-tipiracil (n=31)

26 Nov

Hepatocellular Carcinoma

New Reference: Cabozantinib and Atezolizumab in HCC

Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg

20 Sep

Follicular Lymphoma

New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma

Phase 3, open label, randomized study (RELEVANCE) Untreated grade 1-3a FL R2 (n:513) or R-chemo (n:517), followed by rituximab maintenance

20 Aug

Non-Small Cell Lung Cancer

New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC

A Phase II , Randomized, Open-label , multicenter trial Resectable, stage IIIA or IIIB NSCLC Arm A: Nivolumab + Carboplatin + PaclitaxelS->Nivolumab (n=57) Arm B: Carboplatin +

10 Jan

Hepatocellular Carcinoma

New Protocol: Tremelimumab and Durvalumab for HCC

Open-label, phase 3 trial Unresectable hepatocellular carcinoma and no previous systemic treatment Tremelimumab (300 mg, one dose) plus durvalumab (1500 mg every 4 weeks; STRIDE,

20 Aug

Non-Small Cell Lung Cancer

New Indication: Pembrolizumab for Early-Stage NSCLC

A Phase III placebo-controlled, Randomized, Open-label trial (KEYNOTE-671) Resectable, early stage (stage II and III) NSCLC Arm A: Pembrolizumab + chemotherapyS->Pembrolizumab (

20 Aug

GastroEsophageal Cancer

New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer

Single-arm, multicenter, phase II trial HER2 positive, unresectable or metastatic gastric or gastro-oesophageal junction cancer, progressive disease on or after first-line therapy

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries